Publikationen in Zusammenarbeit mit Forschern von Uppsala University (29)

2024

  1. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

    eClinicalMedicine, Vol. 69

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  4. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  2. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Blood, Vol. 140, Núm. 21, pp. 2248-2260

2021

  1. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

  2. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Leukemia, Vol. 35, Núm. 6, pp. 1745-1750

2020

  1. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

    Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 283-306

  2. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: A multi-center study

    Haematologica, Vol. 105, Núm. 5

  3. Melflufen: A peptide–drug conjugate for the treatment of multiple myeloma

    Journal of Clinical Medicine, Vol. 9, Núm. 10, pp. 1-16

2019

  1. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

    The Lancet Haematology, Vol. 6, Núm. 12, pp. e638-e649

  2. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

    Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106

  3. The Big Data Sjögren consortium: A project for a new data science era

    Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23

2018

  1. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - Update on methodological approaches and results interpretation

    Leukemia, Vol. 32, Núm. 5, pp. 1070-1080

  2. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

  3. Variations in Oxygen Saturation Targeting, and Retinopathy of Prematurity Screening and Treatment Criteria in Neonatal Intensive Care Units: An International Survey

    Neonatology, Vol. 114, Núm. 4, pp. 323-331

2016

  1. Country-Specific vs. Common Birthweight-for-Gestational Age References to Identify Small for Gestational Age Infants Born at 24–28 weeks: An International Study

    Paediatric and Perinatal Epidemiology, Vol. 30, Núm. 5, pp. 450-461

  2. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

    Leukemia, Vol. 30, Núm. 11, pp. 2179-2186